ClinicalTrials.gg
Not yet recruitingNCT07600047Updated Sep 29, 2026

A Well-Being Intervention for People With IBS

An interventional study of Well-Being Intervention in Irritable Bowel Syndrome, sponsored by University of Wisconsin, Madison. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment

Updated Sep 29, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 344 studies in Irritable Bowel Syndrome with a site in United States — 45 open to participants now, 49 under way, 3 of them phase 3. Irritable Bowel Syndrome · United States.

Planned enrollment
84th of 287
150 · median 61
Started
2026
with 16 others
No phase
134 of 344
21 open now
Primary completion
2027-08
later than 33 of 48 live
Registered
338th of 344
by date

Among the 344 studies in Irritable Bowel Syndrome with a site in United States, this one is the 84th largest by planned enrollment of the 287 interventional ones that give a count, is one of 17 that started in 2026, is one of 134 with no phase, reaches primary completion later than 33 of the 48 other live ones, and was the 338th registered.

Irritable Bowel Syndrome

1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

45 of the 344 studies in Irritable Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 344 studies in Irritable Bowel Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this randomized behavioral clinical trial is to examine whether a well-being intervention can improve both psychological well-being and physical outcomes in adults with Irritable Bowel Syndrome (IBS). The study aims to assess whether this intervention decreases anger, anxiety, and depression; increases self-esteem, empathy, and hope; and improves quality of life indicators such as IBS symptom severity, sleep quality, fatigue, and diet. Participants can expect to be on study for up to 9 months.

Read the detailed description

This study consists of two phases:

Study 1 (Screening and Baseline Assessment):

Participants who self-identify as having been diagnosed with IBS and receive care at the University of Wisconsin (UW) Digestive Health Center will complete a battery of self-report questionnaires assessing well-being, anger, anxiety, depression, self-esteem, empathy, hope, sleep quality, fatigue, diet, and IBS symptom severity.

Study 2 (Intervention Phase - registered here):

Eligible participants will be randomized to either an experimental well-being intervention or a waitlist control condition. Participants assigned to the waitlist control condition will not receive the intervention during the initial intervention period but will complete all scheduled assessments. After completion of the first post-test assessment, waitlist participants will receive the same 15-session well-being intervention (crossover design).

The intervention will be held once a week for 15 weeks, lasting approximately one hour per session, conducted in a private meeting room at the Digestive Health Center. Sessions focus on emotional awareness, perspective-taking, and developing the capacity to overcome hurt and resentment toward a person who acted unfairly.

Following completion, both groups will complete post-test and follow-up assessments identical to the baseline questionnaires. Qualitative interviews will be conducted to explore participants' experiences with the intervention.

[Note - so as not to bias participants, specific information about the intervention will be withheld until the study is complete]

03

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • well being
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women currently diagnosed with Irritable Bowel Syndrome (IBS) by a healthcare provider.
  • Able to read and write in English.
  • Willing to complete questionnaires and participate in either the intervention or control group.
  • Capable of providing .
  • Must be a UW Health patient or referred through UW Digestive Health Center.

Exclusion criteria

Exclusion Criteria:

  • Individuals with cognitive impairments or reading difficulties that would interfere with understanding study materials or completing assessments.
  • Individuals unable to provide .
  • Prior participation in a similar intervention study.
  • Non-English speakers (since study materials are in English)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Well-Being Intervention

    Behavioral: Well-Being Intervention

  • Active comparator
    Waitlist Control (delayed Well-Being Intervention)

    Behavioral: Well-Being Intervention

Interventions

  • BehavioralWell-Being Intervention

    The intervention will be once weekly over a 15-week period, lasting approximately one hour per session.

06

What researchers measure

Primary outcomes

  1. Anger measured by PROMIS Anger Scale Score

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Anger Scale is scored from 5-25 where higher scores indicates more anger.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  2. Anxiety measured by PROMIS Anxiety Scale Score

    The PROMIS Anxiety Scale is scored from 7-35 where higher scores indicates more anxiety.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  3. Depression measured by IBS PROMIS Depression Scale Score

    The IBS PROMIS Depression Scale is scored from 8-40 where higher scores indicates more depression.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  4. Fatigue measured by IBS Fatigue 8a Score

    The IBS Fatigue 8a Scale is scored from 8-40 where higher scores indicates more fatigue.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  5. Sleep Disturbance measured by IBS Sleep Disturbance 8b

    The IBS Sleep Disturbance 8b Scale is scored from 8-40 where higher scores indicates more sleep disturbance.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  6. Pain measured by Item 1b of the IBS Symptom Severity Scale

    This item is scored from 0-100 where higher scores indicates increased pain.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  7. IBS Severity Score measured by IBS Symptom Severity Scale

    The IBS Symptom Severity Scale is scored from 0-100 where higher scores indicates more severe IBS symptoms.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  8. Well-Being measured by a 30 item Inventory

    The inventory is scored from 30-180 where higher scores indicates greater level of well-being.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  9. Self-esteem measured by Rosenberg Self Esteem Scale Score

    The Rosenberg Self Esteem Scale is scored from 0-30 where higher scores indicates higher self esteem.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  10. Empathy measured by Empathy Questionnaire

    The Empathy Questionnaire is scored from 0-64 where higher scores indicates higher empathy.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  11. Hope measured by Heart Hope Index Score

    The Heart Hope Index is scored from 12-48 where higher scores indicates greater hope.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  12. Healthy Diet Pattern measured by an IBS Diet Survey

    The Diet Survey is scored from 5-24 where higher scores indicate healthier diet pattern.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

07

Study locations

1 site
  • UW Health Digestive Health Center
    Madison, Wisconsin 53705, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.

Of 307 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 8 months is below that.

Counting every sponsor, half of 359 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 20, 2026
StartEst.
Dec 2026was Sep 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Dec 2026
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Start date Sep 2026→Dec 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07600047
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Dec 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Mark Benson, MD
Contact
mb4@medicine.wisc.edu
608-263-1995
Mark Benson, MD
principal investigator · UW School of Medicine and Public Health

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion